Pharmacotherapy of Plexiform Neurofibromas in Patients with Neurofibromatosis Type 1: Possible Adverse Events and Their Management

    A. M. Pivovarova, M. Yu. Dorofeeva, A. R. Zabrodina … V R Voronina
    Studysummary This study observed that among children with neurofibromatosis type 1 in Russia, selumetinib treatment led to a partial reduction in plexiform neurofibroma volume in 65% of cases, with 56% showing a long-term response without surgery; common side effects included skin rash and hair issues.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on rjdn.abvpress.ru →
    Discuss this study in the Community →